USA flag logo/image

An Official Website of the United States Government

SOLUBILIZATION AND SUSTAINED DELIVERY OF ANTITUMOR AGENTS

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
13696
Program Year/Program:
1990 / SBIR
Agency Tracking Number:
13696
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
AMT, INC.
508 HEARTWOOD RD CHERRY HILL, NJ 08003 CHERRY HILL, NJ 08003
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1990
Title: SOLUBILIZATION AND SUSTAINED DELIVERY OF ANTITUMOR AGENTS
Agency: HHS
Contract: N/A
Award Amount: $49,838.00
 

Abstract:

THE OVERALL OBJECTIVE IS TO PROVIDE A NEW DRUG DELIVERY SYSTEM AND TO ENHANCE THE SOLUBILITY OF EXISTING COMPOUNDS THAT EXHIBIT EXCELLENT ANTITUMOR PROPERTIES BUT ARE INSOLUBLE IN WATER. AQUEOUS SOLUBILITY IS ESSENTIAL FOR I.V. ADMINISTRATION OF ANTITUMOR DRUGS. PHASE I RESEARCH WILL SOLUBILIZE DIAMMINEPLATINUMHYDROXYMALONATE AND (TRANS-1,2-DIAMINOCYCLOHEXANE) PLATINUMHYDROXYMALONATE COMPLEXES BY CONJUGATING THEM TO THE HYDROPHILIC AND BIODEGRADABLE POLYMERIC LIGAND, CARBOXYDEXTRAN, AND TO THE MONOMERIC GLUCOPYRANOSE LIGAND. THESE COMPLEXES ARE SPARINGLY SOLUBLE BUT STABLE IN AQUEOUS SOLUTION, AND THEY EXHIBIT DIFFERENT SPECTRA OF ANTITUMOR ACTIVITY THAN CISPLATIN. CONJUGATION OF THESE COMPLEXES TO CARBOXYDEXTRAN MAY PROVIDE A MECHANISM FOR THE SUSTAINED DELIVERY OF ANTITUMOR AGENTS. THE MERITS OF CONJUGATING POLYMERIC OR MONOMERIC LIGANDS WILL BE ASSESSED FROM THE ANTITUMOR DATA OF THE CONJUGATES. INITIAL SCREENING OF THE NEW CONJUGATES WILL BE DONE AGAINST L1210. THE TUMOR WILL BE INJECTED I.P., AND THE TREATMENT WILL BE I.V. SELECTED CANDIDATES WILL ALSO BE SCREENED AGAINST A PANEL OF SOLID TUMORS. PRELIMINARY NEPHROTOXICITY AND HEPATOTOXICITY STUDIES WILL ALSO BE UNDERTAKEN. THE SUCCESS OF THIS PROGRAM WILL PROVIDE EXPANDED USE OF PLATINUM COMPLEXES IN CANCER CHEMOTHERAPY, AND THIS APPROACH WILL BE EXTENDED TO THE SOLUBILIZATION OF OTHER INSOLUBLE ANTITUMOR PLATINUM AND ORGANIC DRUGS IN PHASE II RESEARCH.

Principal Investigator:

Devinder S Gill
3016571700

Business Contact:

Small Business Information at Submission:

Andrulis Research Corp
7315 Wisconsin Ave #650n Bethesda, MD 20814

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No